TY - JOUR
T1 - De-identification procedures for magnetic resonance images and the impact on structural brain measures at different ages
AU - Alzheimer's Disease Neuroimaging Initiative
AU - Buimer, Elizabeth E.L.
AU - Schnack, Hugo G.
AU - Caspi, Yaron
AU - van Haren, Neeltje E.M.
AU - Milchenko, Mikhail
AU - Pas, Pascal
AU - Hulshoff Pol, Hilleke E.
AU - Brouwer, Rachel M.
N1 - Funding Information:
The authors would like to thank the volunteers in the test–retest reliability study, the participants of the YOUth and ADNI studies, and would like to acknowledge Ivonne Valster-Fokkert and Djoya Verbeij for their effort in the visual MRI quality control. Pilot data of the YOUth: Child & Adolescent cohort: The Consortium on Individual Development (CID) is funded through the Gravitation program of the Dutch Ministry of Education, Culture, and Science and the Netherlands Organization for Scientific Research (NWO grant number 024.001.003). ADNI data: Data collection and sharing for this project was funded by the National Institutes of Health Grant U01 AG024904 and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Funding Information:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Grant/Award Number: 024.001.003; U.S. Department of Defense, Grant/Award Number: W81XWH‐12‐2‐0012; Alzheimer's Therapeutic Research Institute; Northern California Institute for Research and Education; The Canadian Institutes of Health Research; Transition Therapeutics; Takeda Pharmaceutical Company; Servier; Piramal Imaging; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Neurotrack Technologies; NeuroRx Research; Meso Scale Diagnostics, LLC.; Merck & Co., Inc.; Lundbeck; Lumosity; Johnson & Johnson Pharmaceutical Research & Development LLC.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; IXICO Ltd.; GE Healthcare; Fujirebio; F. Hoffmann‐La Roche Ltd and its affiliated company Genentech, Inc.; EuroImmun; Eli Lilly and Company; Elan Pharmaceuticals, Inc.; Cogstate; Eisai Inc.; CereSpir, Inc.; Biogen; Bristol‐Myers Squibb Company; BioClinica, Inc.; Araclon Biotech; Alzheimer's Drug Discovery Foundation; AbbVie, Alzheimer's Association; National Institute of Biomedical Imaging and Bioengineering; National Institute on Aging; Department of Defense, Grant/Award Number: W81XWH‐12‐2‐0012; National Institutes of Health, Grant/Award Number: U01 AG024904 Funding information
Funding Information:
The authors would like to thank the volunteers in the test–retest reliability study, the participants of the YOUth and ADNI studies, and would like to acknowledge Ivonne Valster‐Fokkert and Djoya Verbeij for their effort in the visual MRI quality control. Pilot data of the YOUth: Child & Adolescent cohort: The Consortium on Individual Development (CID) is funded through the Gravitation program of the Dutch Ministry of Education, Culture, and Science and the Netherlands Organization for Scientific Research (NWO grant number 024.001.003). ADNI data: Data collection and sharing for this project was funded by the National Institutes of Health Grant U01 AG024904 and DOD ADNI (Department of Defense award number W81XWH‐12‐2‐0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol‐Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann‐La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Publisher Copyright:
© 2021 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Surface rendering of MRI brain scans may lead to identification of the participant through facial characteristics. In this study, we evaluate three methods that overwrite voxels containing privacy-sensitive information: Face Masking, FreeSurfer defacing, and FSL defacing. We included structural T1-weighted MRI scans of children, young adults and older adults. For the young adults, test–retest data were included with a 1-week interval. The effects of the de-identification methods were quantified using different statistics to capture random variation and systematic noise in measures obtained through the FreeSurfer processing pipeline. Face Masking and FSL defacing impacted brain voxels in some scans especially in younger participants. FreeSurfer defacing left brain tissue intact in all cases. FSL defacing and FreeSurfer defacing preserved identifiable characteristics around the eyes or mouth in some scans. For all de-identification methods regional brain measures of subcortical volume, cortical volume, cortical surface area, and cortical thickness were on average highly replicable when derived from original versus de-identified scans with average regional correlations >.90 for children, young adults, and older adults. Small systematic biases were found that incidentally resulted in significantly different brain measures after de-identification, depending on the studied subsample, de-identification method, and brain metric. In young adults, test–retest intraclass correlation coefficients (ICCs) were comparable for original scans and de-identified scans with average regional ICCs >.90 for (sub)cortical volume and cortical surface area and ICCs >.80 for cortical thickness. We conclude that apparent visual differences between de-identification methods minimally impact reliability of brain measures, although small systematic biases can occur.
AB - Surface rendering of MRI brain scans may lead to identification of the participant through facial characteristics. In this study, we evaluate three methods that overwrite voxels containing privacy-sensitive information: Face Masking, FreeSurfer defacing, and FSL defacing. We included structural T1-weighted MRI scans of children, young adults and older adults. For the young adults, test–retest data were included with a 1-week interval. The effects of the de-identification methods were quantified using different statistics to capture random variation and systematic noise in measures obtained through the FreeSurfer processing pipeline. Face Masking and FSL defacing impacted brain voxels in some scans especially in younger participants. FreeSurfer defacing left brain tissue intact in all cases. FSL defacing and FreeSurfer defacing preserved identifiable characteristics around the eyes or mouth in some scans. For all de-identification methods regional brain measures of subcortical volume, cortical volume, cortical surface area, and cortical thickness were on average highly replicable when derived from original versus de-identified scans with average regional correlations >.90 for children, young adults, and older adults. Small systematic biases were found that incidentally resulted in significantly different brain measures after de-identification, depending on the studied subsample, de-identification method, and brain metric. In young adults, test–retest intraclass correlation coefficients (ICCs) were comparable for original scans and de-identified scans with average regional ICCs >.90 for (sub)cortical volume and cortical surface area and ICCs >.80 for cortical thickness. We conclude that apparent visual differences between de-identification methods minimally impact reliability of brain measures, although small systematic biases can occur.
KW - aged
KW - brain
KW - child
KW - data anonymization
KW - humans
KW - longitudinal studies
KW - magnetic resonance imaging
KW - privacy
KW - reproducibility of results
KW - young adult
UR - http://www.scopus.com/inward/record.url?scp=85105726046&partnerID=8YFLogxK
U2 - 10.1002/hbm.25459
DO - 10.1002/hbm.25459
M3 - Article
C2 - 33973694
AN - SCOPUS:85105726046
SN - 1065-9471
VL - 42
SP - 3643
EP - 3655
JO - Human Brain Mapping
JF - Human Brain Mapping
IS - 11
ER -